Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1521)	10/26/1998 10:54:00 AM
From: David Bogdanoff	Respond to of 2173

To all; Jim McCamants favorably mentioned Amylin today on CNBC as being an especially cheap biotech stock(market cap below cash, I think). More generally, he likes biotechs as a group because of undervaluation, more approved drugs, and a coming wave of takeovers. Does this account for Amylin's strength this morning, or is there some other news? David

To: Rudy Saucillo who wrote (1521)	10/27/1998 9:07:00 PM
From: arnie h	Read Replies (1) \| Respond to of 2173

Rudy, thanks for pointing out the Exendin-4 and GLP-1 analog papers in Medline. I think you are right about possible value being mostly on the side of Exendin-4 at this point especially since the Amylin patents were used to secure the J&J development loan. Still, if there is any value in the pramlinitide research, J&J would probably be happy to negotiate something since at this point they're on the hook for some substantial loans. In addition to Exendin-4, AMLN has a sizeable tax loss carry over. This could be a significant factor in the eyes of someone interested in taking a shot at Exendin-4 and whatever else might be of technical interest. Also wondering about the quality of the scientific staff that will be left after the cut back. Any feel for that? Thanks, Arnie